Activity regimes for 82Rb cardiac PET: Effects on absolute MBF and MPI

Autor: Nana L Christensen, Kirsten Bouchelouche, Camilla Molich Hoff, Jens Nørkær Sørensen, Lars Poulsen Tolbod

Publikováno v: Hoff, C M, Sørensen, J, Christensen, N L, Bouchelouche, K & Tolbod, L P 2022, ' Activity regimes for 82Rb cardiac PET : Effects on absolute MBF and MPI. ', Journal of Nuclear Cardiology, vol. 29, no. 2, pp. 449–460 . https://doi.org/10.1007/s12350-020-02266-2

Background: Selection of optimal tracer activity for 82Rb PET is based on a trade-off between necessary count-statistics in the late static phase and detector saturation in the early blood-pool phase. Administered tracer activity recommended in presc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf4a391812d9357391be29b2bf630280
https://doi.org/10.1007/s12350-020-02266-2

Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes

Autor: Lars C. Gormsen, Søren Nielsen, Kim Brøsen, Esben Søndergaard, Niels Jessen, Nana L Christensen

Publikováno v: Gormsen, L C, Søndergaard, E, Christensen, N L, Brøsen, K, Jessen, N & Nielsen, S 2019, ' Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes ', Diabetologia, vol. 62, no. 7, pp. 1251-1256 . https://doi.org/10.1007/s00125-019-4872-7
Gormsen, L C, Søndergaard, E, Christensen, N L, Brøsen, K, Jessen, N & Nielsen, S 2019, ' Metformin increases endogenous glucose production in non-diabeticindividuals and individuals with recent-onset type 2 diabetes ', Diabetologia, vol. 62, pp. 1251–1256 . https://doi.org/10.1007/s00125-019-4872-7

AIMS/HYPOTHESIS: Metformin is the endorsed first-line glucose-lowering drug for treating patients with type 2 diabetes but despite more than 50 years of use, no consensus has been reached on its mechanisms of action. In this study, we investigated th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e0b0158b83f522fb31317a1f9f5924
https://portal.findresearcher.sdu.dk/da/publications/ae685f44-d9c9-4f7a-85ff-5881f4ad35a3

Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study

Autor: Henrik Wiggers, Lars C. Gormsen, Hendrik J. Harms, Lars Poulsen Tolbod, Esben Søndergaard, Roni Nielsen, Niels Møller, Hans Erik Bøtker, Jakob Hansen, Mads Svart, Mikkel H. Vendelbo, Henrik Holm Thomsen, Nana L Christensen, Niels Jessen

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Gormsen, L C, Svart, M, Thomsen, H H, Søndergaard, E, Vendelbo, M, Christensen, N L, Tolbod, L P, Harms, H J, Nielsen, R, Wiggers, H, Jessen, N, Hansen, J, Bøtker, H E & Møller, N 2017, ' Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study ', Journal of the American Heart Association, vol. 6, no. 3, e005066, pp. 1-11 . https://doi.org/10.1161/JAHA.116.005066

Background High levels of ketone bodies are associated with improved survival as observed with regular exercise, caloric restriction, and—most recently—treatment with sodium–glucose linked transporter 2 inhibitor antidiabetic drugs. In heart fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5611f40ef291a2a23a97afd26fa46b
http://europepmc.org/articles/PMC5524028